泰恩康(301263.SZ):“和胃整腸丸”後續將在全資子公司安徽泰恩康實現大規模工業化生產
格隆匯7月4日丨泰恩康(301263.SZ)近期在接待機構調研時表示,公司將加快推進“和胃整腸丸”國內藥品註冊相關工作及在安徽泰恩康製藥有限公司(以下簡稱“安徽泰恩康”)的生產落地,隨着國內藥品註冊證及生產的落地,“和胃整腸丸”後續將在全資子公司安徽泰恩康實現大規模工業化生產。安徽泰恩康具備良好的中成藥生產基礎及優勢,其原有的丸劑、片劑、顆粒劑生產線均已通過GMP認證,預計在受讓“和胃整腸丸”全套生產技術並獲得國內生產批件後,將快速提高“和胃整腸丸”的國內產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.